Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body’s immune system to target tumors. Despite their initial clinical success, many patients eventually experience diminished therapeutic responses as tumors acquire resistance. A new study from Taiwan now elucidates the underlying mechanisms of this resistance and proposes a promising strategy to counteract it.
If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.
If you want to read more Like this articles, you can visit our Science category.
